Pailin Bio released its 2026 interim report. First-half net profit attributable to the parent was 84.3 million yuan, down 64.2% year on year. Operating revenue was 830 million yuan, down 15.9% year on year. Net profit attributable to the parent after deducting non-recurring items was 64.81 million yuan, down 69.8% year on year. Net operating cash flow was negative 83.87 million yuan, up 56.5% year on year. Second-quarter net profit attributable to the parent was 61.33 million yuan, down 58.2% year on year. The company said the blood products industry has been affected by policies such as expanded centralized procurement and medical insurance cost control, leading to fewer clinical prescriptions and a year-on-year decline in gross margin for the blood products business. However, plasma collection volume reached 845 tonnes, up 9.4% year on year, and the company expects second-half performance to show a low-then-high trend.
Pacific Shuanglin Bio pharmacy Co LtdFirst-half net profit down 64.2% and gross margin decline due to policy impacts.
